Bronchial Fistula Associated with Sunitinib in a Patient Previously Treated with Radiation Therapy

被引:26
作者
Basille, Damien [1 ]
Andrejak, Michel [2 ]
Bentayeb, Houcine [1 ]
Kanaan, Marc [1 ]
Fournier, Clement [3 ]
Lecuyer, Emmanuelle [1 ]
Boutemy, Marie [1 ]
Garidi, Reda [1 ]
Douadi, Youcef [1 ]
Dayen, Charles [1 ]
机构
[1] Ctr Hosp St Quentin, F-02321 St Quentin en Yvelines, France
[2] Ctr Hosp Univ Amiens, Dept Res, Fac Med, Amiens, France
[3] Ctr Hosp Reg Univ Lille, Serv Endoscopie Resp, Clin Malad Resp, Lille, France
关键词
adverse effect; fistula; radiotherapy; renal cell cancer; sunitinib; tumor necrosis; VEGF; GASTROINTESTINAL STROMAL TUMORS; CELL; SORAFENIB; INHIBITOR; RADIOTHERAPY; CAPILLARIES; BEVACIZUMAB; CARBOPLATIN; PACLITAXEL; SU11248;
D O I
10.1345/aph.1M469
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To report a case of bronchial fistula associated with sunitinib in a patient previously treated with radiation therapy CASE SUMMARY: A 40-year-old man with renal cell cancer diagnosed in 2005 and initially treated by radical nephrectomy presented in March 2007 with a recurrence with cerebral, mediastinal, and lung metastases. A thoracic computed tomography (CT) scan showed a subcarinal tumor obstructing the bronchus intermedius. The patient was initially treated with cerebral and thoracic radiotherapy and then with sunitinib 50 mg/day (4 weeks on, 2 weeks off). Two months after the beginning of treatment, a CT scan revealed a dramatic reduction in the size of the tumor, associated with a bronchial fistula. This was confirmed by flexible bronchoscopy, which showed complete necrosis of the tumor and a large perforation of the bronchus intermedius. Sunitinib was immediately withdrawn and antibiotic prophylaxis was instituted. It was not possible to place an endobronchial stent. Two weeks later, flexible bronchoscopy revealed the reappearance of a yellowish mass protruding into the bronchus intermedius (40% obstruction). A few months later, the obstruction of the bronchus intermedius progressed to 90% and was associated with a contralateral obstruction of the left mainstem bronchus (20%). A rigid bronchoscopy was then performed to clear the obstruction and an endobronchial stent was placed, with satisfactory initial results. In February 2008, the patient presented with new bronchial obstruction under the endobronchial stent but refused a rigid bronchoscopy and died in March 2008. DISCUSSION: Sunitinib, a multitarget tyrosine kinase inhibitor with antiangiogenic and antitumoral activities, has been approved for the treatment of advanced renal cell carcinoma. This treatment is generally well tolerated. Serious complications may occur, however. According to the Naranjo probability scale, the bronchial fistula was possibly related to sunitinib treatment. CONCLUSIONS: This is a rare case of a bronchial perforation leading to a fistula associated with sunitinib treatment after mediastinal radiation therapy Clinicians may consider strict follow-up of patients with proximal lung metastases treated with sunitinib (CT scan and, if appropriate, placement of an endobronchial stent).
引用
收藏
页码:383 / 386
页数:4
相关论文
共 24 条
  • [1] Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling
    Baffert, F
    Le, T
    Sennino, B
    Thurston, G
    Kuo, CJ
    Hu-Lowe, D
    McDonald, DM
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2006, 290 (02): : H547 - H559
  • [2] Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma
    Bhojani, Naeem
    Jeldres, Claudio
    Patard, Jean-Jacques
    Perrotte, Paul
    Suardi, Nazareno
    Hutterer, Georg
    Patenaude, Francois
    Oudard, Stephane
    Karakiewicz, Pierre I.
    [J]. EUROPEAN UROLOGY, 2008, 53 (05) : 917 - 930
  • [3] FDA drug approval summary:: Bevacizumab (Avastin®) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer
    Cohen, Martin H.
    Gootenberg, Joe
    Keegan, Patricia
    Pazdur, Richard
    [J]. ONCOLOGIST, 2007, 12 (06) : 713 - 718
  • [4] Sunitinib
    Deeks, Emma D.
    Keating, Gillian M.
    [J]. DRUGS, 2006, 66 (17) : 2255 - 2266
  • [5] Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
    Faivre, S
    Delbaldo, C
    Vera, K
    Robert, C
    Lozahic, S
    Lassau, N
    Bello, C
    Deprimo, S
    Brega, A
    Massimini, G
    Armand, JP
    Scigalla, P
    Raymond, E
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (01) : 25 - 35
  • [6] Sunitinib (sutent)-induced thyrotoxicosis due to destructive thyroiditis: A case report
    Faris, Jason E.
    Moore, Allan F.
    Daniels, Gilbert H.
    [J]. THYROID, 2007, 17 (11) : 1147 - 1149
  • [7] *GEN INC, 2007, IMP DRUG WARN
  • [8] Tracheo-esophageal fistula with bevacizumab after mediastinal radiation
    Goodgame, Boone
    Veeramachaneni, Nirmal
    Patterson, Alexander
    Govindan, Ramaswamy
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (09) : 1080 - 1081
  • [9] Approval summary: Sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma
    Goodman, Vicki L.
    Rock, Edwin P.
    Dagher, Ramzi
    Ramchandani, Roshni P.
    Abraham, Sophia
    Gobburu, Jogarao V. S.
    Booth, Brian P.
    Verbois, S. Leigh
    Morse, David E.
    Liang, Cheng Yi
    Chiclambaram, Nallaperumal
    Jiang, Janet X.
    Tang, Shenghui
    Mahjoob, Kooros
    Justice, Robert
    Pazdur, Richard
    [J]. CLINICAL CANCER RESEARCH, 2007, 13 (05) : 1367 - 1373
  • [10] Sorafenib and sunitinib: Novel targeted therapies for renal cell cancer
    Grandinetti, Cheryl A.
    Goldspiel, Barry R.
    [J]. PHARMACOTHERAPY, 2007, 27 (08): : 1125 - 1144